Abstract:Malignant hematopoietic cells gain metabolic plasticity, reorganize anabolic mechanisms to improve anabolic output and prevent oxidative damage, and bypass cell cycle checkpoints, eventually outcompeting normal hematopoietic cells. Current therapeutic strategies of acute myeloid leukemia (AML) are based on prognostic stratification that includes mutation profile as the closest surrogate to disease biology. Clinical efficacy of targeted therapies, e.g., agents targeting mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 or 2, are mostly limited to the presence of relevant mutations. Recent studies have not only demonstrated that specific mutations in AML create metabolic vulnerabilities but also highlighted the efficacy of targeting metabolic vulnerabilities in combination with inhibitors of these mutations. Therefore, delineating the functional relationships between genetic stratification, metabolic dependencies, and response to specific inhibitors of these vulnerabilities is crucial for identifying more effective therapeutic regimens, understanding resistance mechanisms, and identifying early response markers, ultimately improving the likelihood of cure. In addition, metabolic changes occurring in the tumor microenvironment have also been reported as therapeutic targets. The metabolic profiles of leukemia stem cells (LSCs) differ, and relapsed/refractory LSCs switch to alternative metabolic pathways, fueling oxidative phosphorylation (OXPHOS), rendering them therapeutically resistant. In this review, we discuss the role of cancer metabolic pathways that contribute to the metabolic plasticity of AML and confer resistance to standard therapy; we also highlight the latest promising developments in the field in translating these important findings to the clinic and discuss the tumor microenvironment that supports metabolic plasticity and interplay with AML cells.

Metabolic dysregulation in myelodysplastic neoplasm: impact on pathogenesis and potential therapeutic targets

The Clinical Significance of Iron Overload and Iron Metabolism in Myelodysplastic Syndrome and Acute Myeloid Leukemia

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments

Metabolomics for hematologic malignancies: Advances and perspective

Deregulated microRNA expression and its pathogenetic implications for myelodysplastic syndromes

Therapeutic Targets in Myelodysplastic Neoplasms: Beyond Hypomethylating Agents

Targeting metabolic vulnerabilities to overcome resistance to therapy in acute myeloid leukemia

Beyond HMAs: Novel Targets and Therapeutic Approaches

The molecular pathogenesis of myelodysplastic syndromes

[Recent Advances of Molecular Mechanisms Influencing Prognosis of Myelodysplastic Syndrome - Review].

The Importance of Cellular Metabolic Pathways in Pathogenesis and Selective Treatments of Hematological Malignancies

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives

Epigenetic regulation in myelodysplastic syndromes: implications for therapy

Recent advances in myelodysplastic syndromes

Gut Microbiome and Plasma Metabolomic Analysis in Patients with Myelodysplastic Syndrome.

Metabolic dependencies of acute myeloid leukemia stem cells

Advances in Understanding the Links between Metabolism and Autophagy in Acute Myeloid Leukemia: From Biology to Therapeutic Targeting

Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine

Molecular Targeted Therapy and Immunotherapy for Myelodysplastic Syndrome

Targeted therapies for myelodysplastic syndromes/neoplasms (MDS): current landscape and future directions